Thomas J. Lynch, MD, discusses the treatment of patients with T790M-mutant non-small cell lung cancer (NSCLC).
Thomas J. Lynch, MD
Advertisement
Articles by Thomas J. Lynch, MD
Thomas J. Lynch, MD, discusses challenges associated with treating patients with lung cancer with molecular targeted therapies.
Thomas J. Lynch, MD, Yale Cancer Center, discusses actionable mutations in non-small cell lung cancer (NSCLC).
Advertisement
Latest Updated Articles
Actionable Mutations in NSCLCPublished: April 8th 2014 | Updated:
Challenges Associated With Molecular Targeted Therapies in Lung CancerPublished: January 7th 2015 | Updated:
Treating Patients With T790M-Mutant NSCLCPublished: April 10th 2015 | Updated:
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Grants Traditional Approval to Pirtobrutinib in CLL/SLL
2
Durable Responses With Novel Cell Therapy TARA-002 in BCG-Naive NMIBC
3
LP-184 Demonstrates Favorable Efficacy and Safety in Advanced Solid Tumors
4
JANX007 Shows Promising Efficacy, Safety in Phase 1 Trial Update
5
